Security key
45719W205
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)
CUSIP: 45719W205
Q1 2023 13F Holders as of 31 Mar 2023
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 140,000,283
- Total 13F shares
- 82,817
- Share change
- +82,817
- Total reported value
- $54,460
- Price per share
- $0.66
- Number of holders
- 1
- Value change
- +$54,460
- Number of buys
- 1
Report period
Q1 2023
Institutions
1
Top holders
1
IKT full security history
Newer quarter: Q2 2023
Inhibikase Therapeutics, Inc. SEC filings
Inhibikase Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45719W205
Recent filing periods:
Top shareholders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
—
class O/S missing
|
530,276
|
$265,138 | — | 31 Dec 2022 | |
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
—
class O/S missing
|
229,000
|
$114,500 | — | 31 Dec 2022 | |
| Redmond Asset Management, LLC |
13F
|
Company |
—
class O/S missing
|
125,805
|
$62,903 | — | 31 Dec 2022 | |
| ZEKE CAPITAL ADVISORS, LLC |
13F
|
Company |
—
class O/S missing
|
93,800
|
$46,900 | — | 31 Dec 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
89,048
|
$44,000 | — | 31 Dec 2022 | |
| Joseph Frattaroli |
3/4/5
|
Cheif Financial Officer |
—
mixed-class rows
|
138,091
mixed-class rows
|
$38,473 | — | 01 Mar 2023 | |
| Koshinski Asset Management, Inc. |
13F
|
Company |
—
class O/S missing
|
65,377
|
$32,688 | — | 31 Dec 2022 | |
| STATE STREET CORP |
13F
|
Company |
—
class O/S missing
|
60,500
|
$30,250 | — | 31 Dec 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
—
class O/S missing
|
52,000
|
$26,000 | — | 31 Dec 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
—
class O/S missing
|
39,007
|
$19,504 | — | 31 Dec 2022 | |
| Retirement Planning Co of New England, Inc. |
13F
|
Company |
—
class O/S missing
|
35,212
|
$17,606 | — | 31 Dec 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
—
class O/S missing
|
30,656
|
$15,328 | — | 31 Dec 2022 | |
| CCG WEALTH MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
30,000
|
$15,000 | — | 31 Dec 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
—
class O/S missing
|
28,872
|
$14,436 | — | 31 Dec 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
10,814
|
$5,000 | — | 31 Dec 2022 | |
| MORGAN STANLEY |
13F
|
Company |
—
class O/S missing
|
10,000
|
$5,000 | — | 31 Dec 2022 | |
| SPROTT INC. |
13F
|
Company |
—
class O/S missing
|
10,000
|
$5,000 | — | 31 Dec 2022 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
—
class O/S missing
|
136
|
$68 | — | 31 Dec 2022 | |
| UBS Group AG |
13F
|
Company |
—
class O/S missing
|
130
|
$65 | — | 31 Dec 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
class O/S missing
|
40
|
$20 | — | 31 Dec 2022 | |
| Elizabeth G. O'Farrell |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 24 Jun 2022 |
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q1 2023
As of 31 Mar 2023,
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
82,817 shares.
The largest 1 holders included
HAMILTON LANE ADVISORS LLC.
This page lists
1
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2023 vs Q4 2025 Across Filers
Q4 2025 holders
73
Q1 2023 holders
1
Holder diff
-72
| Investor | Q4 2025 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.